Extract

To determine the efficacy of combination treatment with continued enzalutamide plus abiraterone acetate (abiraterone) and prednisone (or prednisolone) compared with placebo plus abiraterone and prednisone as measured by progression free survival (PFS) after prostate-specific antigen (PSA) progression on treatment with enzalutamide in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (CRPC).

Inclusion criteria

• Patients With Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer

Links

• euctr
• ictrp
• euctr
• ictrp
• euctr
• euctr
• ictrp
• ictrp
• ictrp
• ictrp
• ictrp
• ictrp
• euctr
• euctr
• euctr
• euctr